Pledge Therapeutics

We started with a Pledge to tackle the most challenging drug targets in modern medicine: we are pursuing some of the most sought-after targets in drug discovery

[Ali Munawar @alimunawar]

@JohnCendpts my deepest thoughts & prayers!
Merkel cell #polyomavirus & others including #BKvirus are under appreciated. Given the mention of kidney failure (& possible future transplantation) #BKV is a real threat. Raising awareness is critical. We have developed the first oral, directed, antiviral targeting this family of viruses @PledgeTx @orthogontherapeutics.

[Pledge Therapeutics @PledgeTx]

Deal deep dive:

~70% of private biotech deals are in immunology; high buyer interest in immune-modifying treatment

Multispecific antibody deals dominated Q2; pressure to enhance biologic design is on

3 of 7 biologic deals are cytokine-based; are interleukins the future?

[Pledge Therapeutics @PledgeTx]

Big pharma's top selling medicines are set to lose patent protection, fueling an M&A frenzy.

The first half of this year saw 13 private biotech buyout deals, surpassing the M&A pace set in the last six years.

Will this trend continue?

Sources: BioPharmaDive, AcuityKnowledge

[Pledge Therapeutics @PledgeTx]

This month, we bid farewell to Dominic Lo and Tran Le. Thank you for your contributions to Pledge, and best of luck in medical & graduate school!

As we say goodbye, we're also thrilled to welcome Dr. Nagraj Mani as our new Senior Director of Virology! #Pledge #TeamGrowth

[Pledge Therapeutics @PledgeTx]

🎉This week we celebrate the birthday of Rosalind Franklin (25 July 1920): Trailblazing chemist & crystallographic, her X-ray work was vital in unravelling the DNA structure!🧬 #WomenInScience #WomanInCrystallography #leadership

[Pledge Therapeutics @PledgeTx]

Tremendous news from Orthogon Therapeutics @PledgeTX Antiviral Arm🤩$6M secured for pioneering #BKvirus drug! Our team's dedication and ingenuity bring us closer to delivering the first-ever treatment for #BKvirus! A groundbreaking journey is ahead of us!
https://t.co/tv4QRVrnis

[Ali Munawar @alimunawar]

Once again, our backers have demonstrated their belief in our technology platform and in our mission to develop innovative treatment options for transplant patients https://t.co/nPVcgVD7kh

[Pledge Therapeutics @PledgeTx]

Farewell, @KULeuven Master Students!🎉After an incredible year of hard work and promising results, we celebrate our student's achievements with a BBQ!🍔😋 Best wishes from all of us at @PledgeTx !
#Brightfuture #DreamBig

[Pledge Therapeutics @PledgeTx]

Interesting read!#BKV and JC virus create latent infections of kidney cells; immune changes can trigger reactivation and disease. Understanding their behavior is crucial for #smallmolecule interventions.
@PledgeTx #Polyomavirus #SmallMolecule #research
https://t.co/GSdwXYvZe8

[Judy (Qiuying) Shi, MD. @JudyShi8]

Nice article to read on polyoma virus in urine cytology-@mtsiddi Thank you for sharing your beautiful “comet” “https://t.co/R7SRus4Y25

[Pledge Therapeutics @PledgeTx]

Monday in our #European HQ--Louanne and Cristina are on fire greasing up their #crystallization plates and prepping for a great round of crystal optimization, looking forward to seeing some nice protein crystals soon!
#Lablife #Science #research #investigation #crystallography

[Pledge Therapeutics @PledgeTx]

Cryo-EM has achieved atomic resolution and it unlocks new insights and enhances its role in structure-based #drugdesign. At @PledgeTX we employ CryoEM alongside X-ray crystallography, and these advancements are exciting! #Science #DrugDesign
https://t.co/POAbJ1i5BE

[Pledge Therapeutics @PledgeTx]

What a great week at #BIO2023 Boston! Our Belgian scientists forged an alliance with a llama unleashing a new therapeutics area at @PledgeTx: Hold onto your lab coats as we introduce nanobodies into our therapeutic modalities! #InnovativeTherapeutics #BioTechDiscoveries #research

[Pledge Therapeutics @PledgeTx]

Meet us at the Biotechnology Innovation Organization's #BIO2023 conference in Boston! We are excited to connect with fellow pioneers and industry leaders and collaborate to drive innovation in the field of biotechnology.
#BIO2023 #Boston #BiotechInnovation
#standupforscience

[Pledge Therapeutics @PledgeTx]

Reliable protein models are crucial for #small-molecule #drugdiscovery! @PledgeTx is developing innovative #AI-driven programs to leverage the full potential of prediction data and identify #smallmolecule binders for disease-modifying targets #innovation
https://t.co/bDYguyrPOE

[Pledge Therapeutics @PledgeTx]

It is #SITC2022 week in Boston! We are growing our #ImmuneOncology #Drugdiscovery pipeline and are
excited to discuss the most recent advances in #immunology #immunotherapy
@PledgeTx #drugdiscovery #biotech #SITC22

[Pledge Therapeutics @PledgeTx]

@PledgeTx team had an exciting and productive time at #BioEurope2022! Dr @alimunawar, CEO and @Steff_De_Graef wrapped up a successful week in Leipzig discussing #PledgeTX growing pipeline of #Immuneoncology and #Antivirals assets enabled by our #Drugdiscovery platform

[Pledge Therapeutics @PledgeTx]

Proteins are the origin of most diseases. Scientists at @PledgeTx produce these disease-causing proteins in a high yield and purity and go above and beyond in the number of constructs to identify the one that gives the best-behaved protein! #Drugdiscovery #research #Biotech

[Pledge Therapeutics @PledgeTx]

Congrats to Stephen Weeks, Director of #StructuralBiology and #Biophysics at @PledgeTx for his new publication at @CommsBio about "Partitioning of the initial catalytic steps of leucyl-tRNA synthetase is driven by an active site peptide-plane flip" with @KU_Leuven

[Communications Biology @CommsBio]

Crystal structures for leucyl-tRNA synthetase in N. gonorrhoeae reveal multi-domain conformational changes that correlate with a local peptide-plane flip in the active site to compartmentalize catalytic steps.
@PledgeTx @KU_Leuven @Zagreb_Uni

https://t.co/jGfsjEe7OD

[Pledge Therapeutics @PledgeTx]

Good review summarizing the #ImmuneOncology #smallmolecule landscape. Our team @PledgeTx is developing the next generation of #ImmuneOncology small molecule drugs to complement existing therapeutic modalities. #Drugdiscovery #Biotech #Research #CancerResearch #Innovation

[Nature Reviews Drug Discovery @NatRevDrugDisc]

The expanding role for small
molecules in immuno-oncology https://t.co/B9R1UkCFuc

A new review covering small molecules targeting cancer metabolism, cytokine/chemokine and innate immune pathways and T cell checkpoints that could be complementary to PD1/PDL1 inhibitors

[Pledge Therapeutics @PledgeTx]

Insightful article by @PledgeTx CEO, Dr. @alimunawar: "Early-stage biopharma: An opportunity for strategic investment" via @InvestmentWeek
#biotech #biotechjobs #venturecapital #drugdiscovery #earlystagestartups #newbusinessmodels #innovationstrategy https://t.co/hbKUxtGP5D

[Pledge Therapeutics @PledgeTx]

@PledgeTx #Teamwork #Startup #Biotech #Research #Science #biotechjobs #drugdiscovery #earlystagestartups #newbusinessmodels #researchanddevelopment